Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.

Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ)...

Descripción completa

Detalles Bibliográficos
Publicado en:Inflammatory Bowel Diseases Vol. 24; no. 9; pp. 1876 - 1883
Autores principales: Dubinsky, Marla C., Cross, Raymond K., Sandborn, William J., Long, Millie, Xue Song, Nianwen Shi, Yao Ding, Eichner, Samantha, Pappalardo, Brandee, Ganguli, Arijit, Wang, Anthony
Formato: research tables/charts Journal Article
Publicado: Oxford University Press / USA Sep2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=132835716&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 132835716
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10780998
        N0V
      jtl: Inflammatory Bowel Diseases
      issn: 10780998
      maglogo: N
    pubinfo:
      dt: Sep2018
      vid: 24
      iid: 9
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        132835716
        132835716
        132835716
        10.1093/ibd/izy065
        132835716
      ppf: 1876
      ppct: 7
      formats:
      tig:
        atl: Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
      aug:
        au:
          Dubinsky, Marla C.
          Cross, Raymond K.
          Sandborn, William J.
          Long, Millie
          Xue Song
          Nianwen Shi
          Yao Ding
          Eichner, Samantha
          Pappalardo, Brandee
          Ganguli, Arijit
          Wang, Anthony
        affil: Icahn School of Medicine, Mount Sinai, New York, New York
      sug:
        subj:
          Inflammatory Bowel Diseases Drug Therapy
          Antibodies, Monoclonal Therapeutic Use
          Tumor Necrosis Factor Antagonists and Inhibitors
          Gastrointestinal Agents Therapeutic Use
          Inflammatory Bowel Diseases Complications
          Inflammation
          Human
          Comparative Studies
          Adult
          Descriptive Statistics
          Linear Regression
          Crohn Disease Complications
          Confidence Intervals
          Skin Diseases
          Stomatitis, Aphthous
          Eye Diseases
          Arthropathy, Neurogenic
          Cholangitis, Sclerosing
          Colitis, Ulcerative Complications
          Incidence
          Adult: 19-44 years
      ab: Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti--tumor necrosis factor (anti-TNF) therapies. Methods: Adult IBD patients receiving VDZ or anti-TNFs were identified from the MarketScan claims database from September 28, 2012, through September 30, 2016. Incidence rates of EIMs were compared between the 2 cohorts. Descriptive analyses were performed for all courses of treatment. Generalized linear models estimated the impact of treatment on the likelihood of developing EIMs. Results: Compared with patients receiving anti-TNF therapy, VDZ-treated CD patients were 28% more likely to develop "any EIMs" (adjusted incident rate ratio [IRR], 1.28; 95% confidence interval [CI], 1.02-1.62). Specifically, CD patients treated with VDZ were more likely to develop erythema nodosum (IRR, 4.29; 95% CI, 1.73-10.64), aphthous stomatitis (IRR, 3.73; 95% CI, 1.51-9.23), episcleritis/scleritis (IRR, 2.51; 95% CI, 1.02-6.14), arthropathy (IRR, 1.45; 95% CI, 1.15-1.84), primary sclerosing cholangitis (PSC) (IRR, 7.79; 95% CI, 3.32-18.27), and uveitis/iritis (IRR, 2.89; 95% CI, 1.35-6.18). UC patients receiving VDZ did not have a statistically significant increase in "any EIMs" vs patients receiving anti-TNFs, but were more likely to develop specific EIMs (aphthous stomatitis: IRR, 3.67; 95% CI, 1.30-10.34; pyoderma gangrenosum: IRR, 4.42; 95% CI, 1.00-19.45; and PSC: IRR, 3.44; 95% CI, 1.23-9.68). Conclusions: IBD patients receiving VDZ may be more likely to develop EIMs vs patients receiving anti-TNF therapies. The gut-selective inflammatory control of VDZ may potentially limit its clinical effect on EIM prevention.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N